Precision medicine in psoriatic arthritis: how should we select targeted therapies?. (September 2019)

• Record Type: Journal Article
• Authors: Al-Mossawi, Hussein; Taams, Leonie S; Goodyear, Carl S; Kirkham, Bruce W; McInnes, Iain B; Siebert, Stefan; Coates, Laura C
• Is Part Of: Lancet. Volume 1:Number 1(2019)
• Page Start: e66
• Page End: e73
• Publication Date: 2019-09
• Subjects: Rheumatology -- periodicals; 616.72305
• DOI: 10.1016/S2665-9913(19)30008-6
• Languages: English
• ISSNs: 2665-9913

Abstract

Summary: Psoriatic arthritis (PsA) is a heterogeneous inflammatory arthritis associated with psoriasis. Patients manifest variable presentations with potential involvement of peripheral joints, spine, tendons, skin, and nails. There has been a rapid expansion in targeted treatment options for patients with PsA, but typically less than half of those who receive therapy achieve optimal treatment targets. Many patients respond to second-line or third-line biological therapies, but little evidence exists to guide the choice of therapeutics for each individual. At present, choice of therapy is driven by active clinical disease domains, clinician familiarity with existing treatments, and cost. Here, we review recent data that highlight the potential for personalised, or precision, medicine in PsA and other forms of inflammatory arthritis, noting that this research is still at a preliminary stage. In the future, a combination of detailed immunophenotyping and sophisticated statistical analyses should help to facilitate a personalised medicine approach in PsA, following examples from other clinical areas, such as oncology. This change in approach to the treatment of PsA has the potential to maximise outcomes for patients and to provide optimal therapies without delay.